Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Translational Research

Volumn 149, Issue 4, 2007, Pages 231-235

  Martin, William ^a   Abraham, Roshini ^a   Shanafelt, Tait ^a   Clark, Raynell J ^a   Bone, Nancy ^a   Geyer, Susan M ^b   Katzmann, Jerry A ^a   Bradwell, Arthur ^b   Kay, Neil E ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; M PROTEIN;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN ELECTROPHORESIS; SERUM;

EID: 33947328524     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.11.001     Document Type: Article

References (22)

1. Pascali E., and Pezzoli A. Serum and urine monoclonal immunoglobulins in malignant non-Hodgkin's lymphoma. Acta Haematol 75 (1986) 193-198
2. Pascali E., and Pezzoli A. The clinical spectrum of pure Bence Jones proteinuria. A study of 66 patients. Cancer 62 (1988) 2408-2415
3. Pezzoli A., and Pascali E. Monoclonal Bence Jones proteinuria in chronic lymphocytic leukaemia. Scand J Haematol 36 (1986) 18-24
4. Kyle R.A. Monoclonal gammopathy of undetermined significance. Blood Rev 8 (1994) 135-141
5. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 (2002) 564-569
6. Abraham R.S., Clark R.J., Bryant S.C., Lymp J.F., Larson T., Kyle R.A., et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 48 (2002) 655-657
7. Abraham R.S., Katzmann J.A., Clark R.J., Bradwell A.R., Kyle R.A., and Gertz M.A. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119 (2003) 274-278
8. Bradwell A.R., Carr-Smith H.D., Mead G.P., Tang L.X., Showell P.J., Drayson M.T., et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47 (2001) 673-680
9. Drayson M., Tang L.X., Drew R., Mead G.P., Carr-Smith H., and Bradwell A.R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97 (2001) 2900-2902
10. Katzmann J.A., Clark R.J., Abraham R.S., Bryant S., Lymp J.F., Bradwell A.R., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48 (2002) 1437-1444
11. Dispenzieri A., Lacy M.Q., Katzmann J.A., Rajkumar S.V., Abraham R.S., Hayman S.R., et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 107 (2006) 3378-3383
12. Rajkumar S.V., Kyle R.A., Therneau T.M., Melton L.J., Bradwell A.R., Clark R.J., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 (2005) 812-817
13. Katzmann J.A., Abraham R.S., Dispenzieri A., Lust J.A., and Kyle R.A. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51 (2005) 878-881
14. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13 (2000) 193-207
15. Jelinek D.F., Tschumper R.C., Geyer S.M., Bone N.D., Dewald G.W., Hanson C.A., et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 115 (2001) 854-861
16. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., and Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
17. Kuppers R., Klein U., Hansmann M.L., and Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 341 (1999) 1520-1529
18. Jelinek D.F., Tschumper R.C., Stolovitzky G.A., Iturria S.J., Tu Y., Lepre J., et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1 (2003) 346-361
19. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 (2001) 1625-1638
20. Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med 135 (1975) 62-66
21. Beaume A., Brizard A., Dreyfus B., and Preud'homme J.L. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 84 (1994) 1216-1219
22. Dingli D., Kyle R.A., Rajkumar S.V., Nowakowski G.S., Larson D.R., Bida F.P., et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108 (2006) 1979-1983